Verzenio™
Drug - Verzenio™ (abemacicib) [Eli Lilly and Company]
June 2018
Therapeutic area - Oral Oncology
Initial approval criteria
- Patient must be at least 18 years old AND
- Patient has a diagnosis of advanced or metastatic breast cancer that is
- hormone receptor (HR)-positive AND
- human epidermal growth factor receptor 2 (HER2)-negative AND
- Verzenio is prescribed for use in combination with fulvestrant for patient with disease progression following endocrine therapy OR
- Vernezio is prescribed as monotherapy for patient with disease progression following endocrine therapy and prior chemotherapy
- Initial approval will be for 6 months
Renewal criteria
- Patient continues to meet initial review criteria AND
- Tumor response with stabilization of disease or decrease in size of tumor or tumor spread AND
- Absence of unacceptable toxicity (e.g., increased ALT/AST)
- Renewal approval will be for 6 months
Quantity limits
56 tablets (4 blister packs) per 28 days
Questions?
MHCP Provider Call Center 651-431-2700 or 800-366-5411